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A b s t r a c t 
Introduction: Restenosis (RS) following percutaneous angioplasty (PTA) of renal artery stenosis (RAS) might have an unfavoura-
ble impact on renal function and blood pressure (BP) outcomes. 
Aim: To evaluate the prevalence and predictors of RS in patients treated with PTA for RAS, and the relationship between BP and 
renal function (RF) changes with RS.
Material and methods: We analysed freedom from RS in 210 patients (age 64.6 ±12.8 years; range: 20–85), who underwent 
248 successful stent-assisted PTAs in RAS. The change in levels of serum creatinine (SCC), estimated glomerular filtration rate 
(eGFR), systolic/diastolic BPs (SBP/DBP) were analysed prior to PTA, at 6-, 12-month, and final follow-up visits, and whenever RS 
was diagnosed. 
Results: RS was identified in 30 (14.3%) patients, and there were 36 (14.5%) lesions. The Kaplan-Meier RS-free survival curves 
in fibromuscular dysplasia, atherosclerosis, and vasculitis at 1 and 7 years were: 100% and 100%; 95.6 and 83.9%; and 71.4 and 
39.7%, respectively. Patients with RS, as compared to RS-free patients, presented with less pronounced changes in respect with: 
SBP (1.4 ±17.6 vs. –15.8 ±25.8 mm Hg; p = 0.01), DBP (2.64 ±10.1 vs. –6.5 ±14.1 mm Hg; p = 0.002),  SCC (22.4 ±55.2 vs. –3.6 
±43.9 µmol/l; p = 0.002),  and eGFR (–1.85 ±18 vs. –5.34 ±19.5 mm Hg; p = 0.045). In multivariate Cox regression analysis, independ-
ent predictors of RS occurred: lack of BP decrease (HR = 4.19, 95% CI: 1.67–10.3; p  = 0.002), eGFR increase < 0.17 ml/min/1.73 m2 
(HR = 2.93, 95% CI: 1.08–7.91; p  =  0.033), stent diameter ≤ 5 mm (HR = 2.76, 95% CI: 1.09–6.97; p = 0.031), and vasculitis 
(HR = 5.61, 95% CI: 1.83–17.2; p  = 0.003). RS was treated in 24 patients with RS recurrence in 20%. 
Conclusions: The RS rate differs depending on RAS aetiology. Lack of SBP/DBP and eGFR improvement, vasculitis, and stent 
diameter are associated with RS risk. Repeated PTA is effective, but recurrent RS occurs in 20% of cases.
Key words: renal artery endovascular treatment, restenosis incidence, predictors of restenosis, primary and secondary patency.
S u m m a r y
Restenosis (RS) following percutaneous angioplasty (PTA) of renal artery stenosis (RAS) might have an unfavourable 
impact on renal function and blood pressure (BP) outcomes. We demonstrated in a group of 210 patients with 248 treated 
lesions, who underwent successful PTA procedure for RAS, that the average RS rate was 14%, accounting for 60% in inflam-
matory, 17% in atherosclerotic, and 0% in fibromuscular dysplasia RAS. Lack of the systolic blood pressure/diastolic blood 
pressure and estimated glomerular filtration rate improvement following PTA, as well as inflammatory aetiology and lower 
stent diameter, were associated with 4.19-, 2.93- 5.61-, and 2.76-fold risk increase of RS, respectively. Repeated PTA was 
effective, but recurrent RS occurred in 20% of cases.
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Introduction
Percutaneous transluminal angioplasty (PTA) is a ther-
apeutic option in patients with symptomatic renal artery 
stenosis (RAS) [1–3]. In fibromuscular dysplasia (FMD) 
this kind of treatment is the first-line therapy, whereas in 
atherosclerotic stenosis indications for PTA are limited to 
special clinical settings. The use of stents is determined 
by the RAS aetiology and anatomy [3, 4]. 
The immediate result of PTA is characterised by 
a  high success rate and fairly low periprocedural com-
plication rate [5–7]. However, the clinical improvement 
following PTA of RAS is uncertain [5–8]. The effect of PTA 
is probably a complex issue, as both the effect of PTA on 
renal function and systolic/diastolic blood pressure (SBP/
DBP), as well as cardiovascular adverse events is at least 
controversial [6, 9, 10]. Furthermore, the long-term result 
of PTA is limited by the unwelcome occurrence of recur-
rent stenosis (RS) that may additionally impact the final 
effect of PTA. The RS rate following RAS procedures is es-
timated at 6–40% [5–8, 11]. However, the determinants 
of RS are poorly established. 
Among the potential risk factors of RS following PTA, 
the RAS aetiology, the presence of previous cardiovas-
cular disease, RAS severity exceeding 90%, bare metal 
stent (BMS) use, or renal artery reference calibre are 
mentioned [12–14]. Protective use of statins before PTA 
was postulated [15]. Nevertheless, data concerning the 
determinants of RS following PTA for RAS are rather in-
consistent and poorly demonstrated. 
Furthermore, the optimal treatment of  RS  has not 
been established. Potential treatment options include: 
balloon angioplasty with or without drug coating, cutting 
balloon angioplasty or deployment of a second conven-
tional stent, repeat stenting with drug-eluting stents, or 
endovascular brachytherapy [16–18]. Other innovative 
modalities include: polytetrafluoroethylene (PTFE)-cov-
ered stents or carbon coating stents [16–18]. However, 
their long-term effects remain unknown.
Aim
Therefore, the aim of our study was to determine pre-
dictors of primary RS and the results of RS treatment in 
patients with symptomatic RAS following endovascular 
treatment.
Material and methods
In this prospective all-comers study, 210 patients 
aged 64.6 ±12.8 years (20–85) underwent 248 success-
ful PTAs of RAS, with or without stent implantation. Thir-
ty-nine patients underwent bilateral PTAs. We analysed 
freedom from the RS in index lesion.
Inclusion criteria were de novo unilateral or bilateral 
RAS of at least 60% with either accelerated hypertension 
despite three or more blood lowering medications, includ-
ing at least one diuretic, drug-resistant hypertension (SBP 
and/or DBP values of > 140 mm Hg and/or 90 mm Hg, 
respectively), despite the aforementioned pharmacologi-
cal treatment, and/or hypertension crisis.
Also, patients with progressive renal impairment 
and/or episode of acute renal failure associated with an-
giotensin-converting enzyme inhibitor (ACEI) treatment 
were included in the present study. Other inclusion cri-
teria were pulmonary flash oedema, congestive heart 
failure, or severe angina/acute coronary syndrome that 
could not been explained by coronary artery status.
Patients with well controlled BP on blood lowering 
agents or renal atrophy (kidney length < 7 cm in women 
and < 8 cm in men), and patients not willing to partici-
pate in the study or with a follow-up period shorter than 
6 months following PTA were excluded from the present 
study.
The prevalence of the cardiovascular risk factors was 
evaluated. Blood samplings for renal function assess-
ment were collected on patient admission to the depart-
ment, prior to any intervention, immediately after signed, 
informed consent was obtained from the patients. 
Baseline and the change in levels of serum creati-
nine (SCC), eGFR, SBP, and DBP as well as the number of 
blood lowering regiments were analysed prior to PTA, at 
12-month and final follow-up (F-U) visits, and whenever 
at the point of RS diagnosis. 
The glomerular filtration rate was estimated from the 
Modification of Diet in Renal Disease (MDRD) formula, ac-
cording to following equation: MDRD = 175 × creatinine 
[mg/dl] – 1.154 × age [years] – 0.203 × 0.742 [if female].
SBP and DBP measurements were performed in com-
pliance with the Seventh Report of the Joint National 
Committee on Prevention, Detection, Evaluation, and 
Treatment of High Blood Pressure: the JNC 7 report pub-
lished in 2003 and ESH/ESC Guidelines for the manage-
ment of arterial hypertension published in 2013 [19, 20]. 
In brief, the mean SBP and DBP value was averaged from 
at least two BP measurements, preceded by 5 min of rest 
and repeated within a two-minute interval.
The study protocol was reviewed and approved by the 
Local Ethical Committee. All the patients gave their in-
formed consent for participation in the study. The study 
was performed in accordance with the Declaration of 
Helsinki.
Revascularisation procedure for RAS
Renal angiography was performed from radial or fem-
oral vascular access using a Coroscop system (Siemens 
AG, Munich, Germany) equipped with Quantcor version 
4.0 quantitative analysis software. Angiography was per-
formed in two modified projections that best displayed 
the lesion. Eligibility criteria were determined on the ba-
sis of contemporary published guidelines for percutane-
ous revascularisation of the RAS [1–3].
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Patients were premedicated with a  loading dose 
of aspirin of 300 mg, followed by 75 mg/day given in-
definitely, and a loading dose of clopidogrel of 300 mg, 
followed by 75 mg/day for 1 to 6 months. During the 
procedure unfractionated heparin was administrated ac-
cording to patient weight and ACT. Periprocedurally, rou-
tinely patients were given 1.5–2.0 l of fluids IV to prevent 
contrast-induced nephropathy. 
The significance of RAS was determined by quanti-
tative angiography (COROSCOP, Siemens, and Quantcor 
QCA V4.0 software for quantitative analysis, Erlangen, 
Germany). An RAS range of 50–69% of diameter of ste-
nosis was assumed borderline, and additional invasive 
criteria were taken into consideration to confirm RAS sig-
nificance (resting mean translesional pressure gradient 
> 10 mm Hg, systolic pressure gradient > 20 mm Hg, or re-
nal fractional flow reserve induced by dopamine 50 µg/kg, 
rFFR ≤ 0.8). 
The first-line revascularisation technique in FMD-re-
lated RAS was PTA without stenting. Atherosclerotic le-
sions were treated with PTA with stent implantation, and 
a renal protection device was used in 1 case. RAS caused 
by vasculitis was managed with stenting, favouring drug 
eluting stent (DES) implantation. DES was also preferred 
in patients with a single functioning kidney, small vessel 
diameter, and when the patient had a history of restenot-
ic lesion in the other arterial bed. 
Balloons were sized to the diameter of the reference 
segment of the vessel, and the patient’s symptoms were 
assessed during each balloon inflation. 
During revascularisation procedure, predilatation vs. 
direct stenting technique depended on the clinical cir-
cumstances and the operator’s decision. In all cases with 
stent implantation, a balloon expandable stent was used. 
The choice of stent was conditioned by the operator’s 
decision, taking into account a  variety of factors such 
as vessel anatomy, treated lesion, and stent availability. 
As a consequence, a heterogeneous group of stents was 
implanted. Procedural success was defined as residual 
diameter stenosis less than 30%. 
RS was defined as recurrence of at least 50% reduc-
tion of the arterial lumen diameter within the stent or 
the adjacent 5 mm of vessel segments. When symptom-
atic RS was confirmed the patient was refed for repeated 
revascularisation.
Primary patency was defined as patency of the target 
lesion following endovascular intervention, and second-
ary patency as the final patency of the target lesion after 
re-intervention.
Follow-up period
The study participants were evaluated at 6 and 12 
months after the procedure in the outpatient setting. 
Thereafter, the assessment was performed at yearly in-
tervals. The follow-up evaluation included clinical assess-
ment, blood pressure and renal function measurement, 
and duplex ultrasonography (DUS). If the patient died 
between month 6 and 12, the parameters from the last 
follow-up visit were taken into statistical analysis.
Hypertension cure was defined as BP values below 
140/90 mm Hg in patients with withdrawn hypertensive 
medications. 
During the median observation period of 48 (Q1; 
Q3: 23; 80) months, the incidences and predictors of RS, 
treatment for RS, and recurrent RS were analysed. 
RS was initially diagnosed with DUS based on the 
peak-systolic aortic and renal artery velocities and in-
tra-renal flow parameters [21]. The RAS was confirmed 
with either CT-angiography or directly during the invasive 
angiography preceding the PTA procedure. In some pa-
tients stenosis severity was established with translesion-
al resting and hyperaemic gradients. Data on RS were 
collected during the follow-up visits. 
Statistical analysis
The Student’s t-test was used for comparison of con-
tinuous variables, and a  χ2 test was used to compare 
proportions of categorical variables. Means of the anal-
ysed parameters across groups were tested by analysis 
of variance test. Frequencies were compared by χ2 test 
for independence.
We analysed the influence of renal function and BP 
parameter changes, as well as patient-and procedure-re-
lated factors on the incidence of RS and recurrent RS. To 
ensure reliable cut-off values of BP and renal function 
parameter changes, which were potentially associated 
with risk of RS, Receiver Operating Characteristic (ROC) 
curves were constructed. The area under the ROC curve 
(AUC) was calculated as well as the 95% confidence in-
terval (CI). The ROC analysis was followed by the uni- and 
multivariate Cox model.
To establish the factors that could affect RS incidence, 
the clinical, procedural, and angiographic variables were 
assessed by a Cox univariate hazard analysis, and in cas-
es with a trend toward a difference (p < 0.15), they were 
included in a multivariate stepwise Cox proportional haz-
ards analysis. The results of the multivariate Cox propor-
tional hazards analysis were expressed as hazard ratio 
(HR) and 95% confidence interval (CI). 
Seven-year Kaplan-Meier RS-free survival curves for 
primary and secondary target lesion patency, as well as 
RS rate depending on RAS aetiology were constructed. 
Statistical analyses were performed with Statistica 
version 13.0 software (StatSoft, Inc., Tulsa, OK). P < 0.05 
was considered statistically significant.
Results
Baseline clinical and procedural characteristics of 
the study participants are presented in Table I. In brief, 
out of 210 patients with 248 lesions referred to PTA, 225 
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(90.8%) lesions were diagnosed with atherosclerosis, 
9 (3.6%) with fibromuscular dysplasia (FMD), 10 (4%) 
with vasculitis, and the remaining 4 (1.6%) with trau-
ma-related vessel injury resulting in RAS. All FMD-relat-
ed lesions underwent successful balloon angioplasty 
without stenting because there was no indication for 
stent implantation after balloon angioplasty. All arteri-
tis-related lesions were stented, while only two athero-
sclerosis-related RAS underwent plain balloon angio-
plasty. 
Arterial hypertension was diagnosed in all subjects, 
while renal failure (eGFR < 60 ml/min/1.73 m2) was di-
agnosed in 125 (59.2%) patients. Unilateral PTA was per-
formed in 139 (66.2%) patients, and bilateral or PTA of 
the one functioning kidney in 39 (18.6%) and 32 (15.2%) 
patients, respectively. The mean stenosis diameter be-
fore PTA in the whole study group was 73.6 ±15.5%, 
and it was reduced to 13.5 ±8.5% post PTA. In particu-
lar, the stenosis degree was reduced from 80.4 ±30% to 
11.6 ±12% in arteritis-related RAS, from 73.5 ±13.9% to 
13.9 ±9.3% in atherosclerotic RAS, and from 75.1 ±10 to 
12 ±9% in FMD-related lesions (p = NS). DES were im-
planted in 25 (10.1%) and BMS in 212 (85.5%), while 
plain balloon alone as the ultimate method of revascu-
larisation was performed in 11 (4.4%) lesions. 
Median follow-up was 48 months (Q1, Q3: 23, 80 
months). Mean SBP and DBP values after PTA, as com-
pared to baseline values, were significantly reduced from 
150.2 ±24.6 to 132.2 ±18.2 mm Hg (p < 0.001), and from 
82.5 ±13.4 to 75.4 ±11.5 mm Hg (p < 0.001), respectively. 
Also, the number of blood lowering agents was reduced 
significantly from 3.5 ±1.3 to 3.2 ±1.4 (p = 0.003) (Fig-
ure 1). In line, significant mean eGFR increased from 54.5 
±23 to  59.4 ±3.9 ml/min/1.73 m2 (p = 0.001), but no SCC 
(p = 0.299) were observed (Figure 1). 
During the follow-up period, RS was identified in 36 re-
vascularized vessels, in 30 (14.4%) patients. Patients with 
diagnosed RS in comparison to the non-RS group were 
characterised by higher prevalence of hyperlipidaemia 
(p = 0.007) and diabetes (p = 0.07), inflammatory aeti-
ology of revascularised lesion (p < 0.002), use of predila-
tation (p = 0.006), and more frequently had lower stent 
diameter (p = 0.001) (Table II). 
Patients at the point of RS identification, as com-
pared to RS-free patients, presented with lack of clinical 
response in terms of changes in SBP (1.4 ±17.6 vs. –15.8 
±25.8 mm Hg; p = 0.01) and DBP (2.64 ±10.1 vs. –6.5 
±14.1 mm Hg; p = 0.002) and clear noticeable deterio-
ration of renal function: SCC (22.4 ±55.2 vs. –3.6 ±43.9 
µmol/l; p = 0.002), as well as eGFR (–1.85 ±18 vs. –5.34 
±19.5 mm Hg; p = 0.045) (Table III).
SBP decrease of less than –1 mm Hg (AUC = 0.778; 
95% CI: 0.66–0.86; p < 0.001; sensitivity: 75%; spec-
ificity: 77%), DBP less than –2 mm Hg (AUC = 0.720; 
95% CI: 0.63–0.81; p < 0.001; sensitivity: 77%; speci-
Table I. Baseline clinical and procedural characte-
ristics of the study participants (n = 210)
Parameter Value
Age, mean ± SD (range) [years] 64.6 ±12.8 (20–85)
Men, n (%) 109 (51.9)
RAS aetiology, n (%):
Atherosclerosis 192 (91.4)
Fibromuscular dysplasia 6 (2.9)
Vasculitis 8 (3.8)
Other (vessel injury) 4 (1.9)
Hypertension, n (%) 210 (100)
Diabetes mellitus, n (%) 63 (30)
Hyperlipidaemia, n (%) 192 (91.4)
Smoking history, n (%) 92 (43.8)
Renal impairment with  
eGFR* < 60 ml/min/1.73 m2, n (%)
125 (59.2)
Previous myocardial infarction, n (%) 32  (15.2)
Previous coronary revascularisation  
(PCI, CABG**), n (%)
89 (42.3)
Previous peripheral revascularisation, n (%) 56 (26.6)
Previous  ischaemic stroke /transient  
ischaemic attack, n (%)
22 (10.4)
Coronary artery disease, n (%) 138 (65.7)
Carotid, vertebral or subclavian artery > 50% 
lumen diameter stenosis, n (%)
89 (42.4)
Lesions characteristics and primary procedure overview (n = 248):
Unilateral PTA, n (%) 139 (66.2)
 Bilateral PTA, n (%) 39 (18.6)
PTA of the artery supplying one functioning 
kidney RAS, n (%)
32 (15.2)
RAS of right renal artery, n (%) 121 (48.8)
RAS of left renal artery, n (%) 127 (51.2)
Mean stenosis severity before PTA,  
mean ± SD, (range) (%)
73.6 ±15.5 
(50–100)
Mean stenosis severity after primary PTA, 
mean ± SD, (range) (%)
13.5 ±8.5 (1–40)
Transfemoral access, n (%) 239 (96.4)
Radial/brachial access, n (%) 5 (2)
Double access (staged procedure), n (%) 4 (1.6)
Balloon angioplasty alone (per successful 
PTA/per patient), n (%)
11 (4.4)/8 (3.8)
Stent implantation, n (%) 237 (95.5)
Drug-eluting stent implantation, n (%) 25 (10.5)
Bare metal stent implantation, n (%) 212 (85.5)
1 stent for one lesion (per stent  
implantation), n (%)
227/237 (95.8)
≥ 2 stents for one lesion (per stent  
implantation), n (%)
10/237 (4.2)
Mean stent length, mean ± SD (range) [mm] 16.2 ±4 (7–36)
Mean stent diameter, mean ± SD (range) 
[mm]
5.6 ±1.4 (3.0–8.0)
Direct stenting (per stent implantation), n (%) 155 (65.4)
Predilatation (per stent implantation), n (%) 82 (34.6)
eGFR – glomerular filtration rate estimated by MDRD formula. PCI – percutane-
ous coronary intervention, CABG – coronary artery bypass grafting.
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Figure 1. Baseline vs. 12-month values for: A – sys-
tolic blood pressure (SBP), B – diastolic blood pres-
sure (DBP), C – number of blood lowering medi-
cations, D – serum creatinine concentration (SCC), 
E – estimated glomerular filtration rate (eGFR) by 
MDR formula
ficity: 63%), SCC increase of 22 µmol/l (AUC = 0.621; 
95% CI: 0.51–0.72; p = 0.019), as well as no decrease of 
eGFR (AUC = 0.621; 95% CI: 0.51–0.72; p = 0.020), and 
stent diameter equal or lower than 5 mm (AUC = 0.683; 
95% CI: 0.58–0.77; p = 0.002) were identified as the best 
cut-off values to discriminate the risk of RS by the ROC 
analysis. These cut-off values were analysed with univar-
iate Cox proportional hazard analysis initially, followed by 
the multivariate Cox analysis (Table IV). 
In multivariate Cox regression analysis: lack of BP de-
crease (HR = 4.19, 95% CI: 1.67–10.3; p = 0.002), eGFR 
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Table II. Comparison of clinical, angiographic, and procedural data in patients and lesions with RS (n = 30/36) 
and without RS (n = 180/212)
Patients’ characteristics Patients with RS
(n = 30)
Patients without RS  
(n = 180)
P-value
Age, mean ± SD (range) [years] 62.2 ±14.9 64.8 ±11.5 0.291
Male gender, n (%) 14 (46.7) 95 (52.7) 0.806
Coronary artery disease, n (%) 19 (63.3) 119 (66.1) 0.840
Supra-aortic involvement, n (%) 15 (50) 74 (41.1) 0.525
Peripheral artery disease, n (%) 6 (20) 59 (32.8) 0.073
History of myocardial infarction, n (%) 4 (13.3) 28 (15.6) 0.815
History of  ischemic stroke/TIA, n (%) 3 (10) 19 (10.6) 0.980
History of  percutaneous coronary intervention, n (%) 12 (40) 54 (30) 0.246
History of CABG, n (%) 5 (16.7) 29 (16.1) 0.878
History of  peripheral artery endovascular treatment, n (%) 7 (23.3) 41 (22.8) 0.753
Hypertension, n (%) 30 (100) 180 (100) 1
Diabetes mellitus, n (%) 12 (40) 51 (28.3) 0.070
Hyperlipidaemia, n (%) 24 (80) 173 (96.1) < 0.001
Smoking history, n (%) 11 (36.7) 81 (45) 0.491
Renal impairment with eGFR* < 60 ml/min/1.73 m2, n (%) 14 (46.7) 111 (61.7) 0.494
RAS aetiology (per lesion): < 0.001
Atherosclerosis, n (%) 30 (83.4) 195 (92)
Fibromuscular dysplasia, n (%) 0 (0) 9 (4.2)
Vasculitis, n (%) 5 (13.8) 5 (2.4)
Other, n (%) 1 (2.8) 3 (1.4)
Lesions’ characteristics Restenotic lesions 
(n = 36)
Non-restenotic 
lesions (n = 212)
P-value
Right renal artery disease treated with PTA, n (%) 17 (47.2) 104 (49.1) 0.819
Left renal artery disease treated with PTA, n (%) 19 (52.8) 108 (50.9)
Mean degree of stenosis (%):
Before primary PTA, mean ± SD (range) 74 ±19.5 (50–100) 73.6 ±14 (50–100) 0.462
After primary PTA, mean ± SD (range) 16.3 ±11.1 (3–40) 13.4 ±9.2 (1–33) 0.428
DES implantation (per stenting), n (%) 3 (12) 22 (88) 0.632
Bare metal stent implantation (per stenting), n (%) 33 (15.6) 179 (84.4)
1 stent for one lesion (per stent implantation), n (%) 34 (94.4) 193 (96) 0.670
≥ 2 stents for one lesion (per stent implantation), n (%) 2 (5.6) 8 (4)
Mean stent length ± SD (range) [mm] 15.3 ±4.9 (7–36) 16.4 ± 3.7 (12–34) 0.555
Mean stent diameter ± SD (range) [mm] 5.3 ±1 (3.0–8.0) 5.6 ±1.3 (4.5–8) 0.001
Maximal inflation pressure ± SD (range) [atm] 14.4 ±3.8 (8–25) 13.9 ±2.8 (8–22) 0.054
Direct stenting (per stent implantation), n (%) 17 (47.2) 140 (69.6) 0.058
Predilatation (per stent implantation), n (%) 19 (52.8) 61 (30.4) 0.006
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95% CI: 1.08–7.91; p = 0.033), stent diameter ≤ 5 mm 
(HR = 2.76; 95% CI: 1.09–6.97; p = 0.031), and inflam-
matory aetiology of RAS (HR = 5.61; 95% CI: 1.83–17.2; 
p =  0.003) occurred as independent predictors of RS risk 
increase (Table IV).
The 7-year Kaplan-Meier RS-free survival rate in the 
whole group was 82.5% for primary and 96.5% for second-
ary patency. Curves differed significantly depending on the 
RAS aetiology (Figure 2 A). The rates of freedom from RS 
at 1, 2, 3, and 7 years after PTA were 100% in FMD, while 
95.6, 92, 88, and 83.9% in atherosclerosis, as well as 71.4, 
39.7, 39.7, and 39.7% in vasculitis (p < 0.001).
During mean follow-up, overall 28/36 (77.8%) lesions 
in 24/30 (80%) patients were referred for further invasive 
assessment. Of those, 15 focal and 13 diffused restenotic 
lesions were confirmed on angiography and referred for 
re-PTA. The remaining 6 patients with RS, after detailed 
evaluation of clinical and haemodynamic data, were ar-
ranged in the observational group and continuation of 
medical therapy.
In patients treated with rePTA the baseline vessel di-
ameter at the point of RS was 74.6 ±16.1%, and it was 
reduced to 19.4 ±10% after re-intervention. Secondary 
success rate defined as residual diameter stenosis less 
than 30% was 91.7% (22 out of 24 patients). 
The re-PTA intervention comprised balloon angio-
plasty alone in 14 lesions, drug eluting balloon in 7, bare 
metal stent implantation in 1, and drug eluting stent im-
plantation in 6.
Recurrent RS was noted in 5 out of 24 (20.8%) pa-
tients/5 out of 28 (17.8%) lesions treated with index rePTA.
The Kaplan-Meier RS-free survival rates were 93.4, 
85.2, and 84.1% for primary RS, and 99.5, 98.1, and 
95.7% for secondary patency at 1, 3, and 5 years after 
PTA, respectively (Figure 2 B).
Discussion
RAS is the most common cause of secondary hyper-
tension with incidence estimated between 1% and 5% in 
the general population [22, 23]. In patients with athero-
sclerotic lesions recognised in coronary or supra-aortic 
arterial beds, the prevalence of RAS is much higher, be-
tween 10–20% [24–26]. 
Invasive lesion management has been a treatment op-
tion for patients with malignant or resistant hypertension, 
hypertension crisis, or pulmonary flash oedema, when 
the effect of blood lowering treatment is suboptimal, and 
includes a  variety of techniques such as percutaneous 
stent-assisted angioplasty or surgical reconstruction [27].
All endovascular procedures are affected by recurrent 
stenosis, and this main drawback of PTA of RAS has an 
average reported incidence rate of between 6.5% and 
40% [18]. However, univocally different risk factors for RS 
in extra-coronary territory are postulated [28–30].
The effect of stent implantation in atherosclerotic 
origin RAS, compared to medical treatment alone, has 
a  small impact on BP control, and an even weaker im-
pact on renal function preservation in the majority of 
randomised clinical trials, but better results have been 
reported in single-centre cohort studies [5, 31]. 
Furthermore, the diagnosis of RS is limited by the 
blurred clinical picture. Firstly, the impact of PTA on BP 
Table III.  Comparison of baseline and follow-up parameters of renal function and blood pressure in groups 
with and without restenosis
Baseline renal function and blood pressure Patients with RS
(n = 30)
Patients without RS 
(n = 180)
P-value
Initial creatinine level, mean ± SD [μmol/l] 128.6 ±55 129.4 ±59.3 0.937
Initial eGFR, mean ± SD [ml/min/1.73 m2] 55.8 ±26.5 53.7 ±22.2 0.626
Initial systolic blood pressure, mean ± SD [mm Hg] 146.9 ±17.3 150.9 ±25.2 0.408
Initial diastolic blood pressure, mean ± SD [mm Hg] 79.7 ±12.7 83.1 ±13.2 0.169
Follow-up parameters at RS diagnosis or 12-months follow-up data  
in patients without RS:
Creatinine level, mean ± SD [μmol/l] 149.7 ±81.8 124.7 ±65.8 0.049
eGFR, mean  ± SD [ml/min/1.73 m2] 53.5 ±29.2 59.4 ±23.7 0.183
Systolic blood pressure, mean ± SD [mm Hg] 150 ±13.1 133.8 ±17.8 < 0.001
Diastolic blood pressure, mean ± SD [mm Hg] 83 ±9.3 76.8 ±11.6 0.010
Change in creatinine level at follow-up vs. initial 22.5±55.2 –3.6 ±43.8 0.002
Change in eGFR level at follow-up vs. initial level –1.8 ±18 5.3 ±19.4 0.044
Change in SBP value at follow-up vs. initial SBP 1.3 ±17.6 –15.8 ±25.8 0.009
Change in DBP value at follow-up vs. initial SBP 2.6 ±10 –6.5 ±14.1 0.010
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Table IV. Univariate and multivariate Cox proportional hazards analysis for risk of restenosis. Only parameters 
with p-value < 0.1 in a Cox univariate hazard analysis were included in a multivariate stepwise Cox proportional 
hazards analysis
Parameters associated with restenosis Univariate Cox
HR (95% CI); p-value
Multivariate Cox
HR (95% CI); p-value
Baseline data
Age 0.98 (0.95–1.01); 0.278 –
Male gender 0.88 (0.42–1.86); 0.750 –
Vasculitis vs. other aetiologies 9.52 (3.75–24.2); < 0.001 5.61 (1.83–17.2); 0.003
Hypertension n/a n/a
Diabetes mellitus 1.71 (0.98–3.76); 0.061 1.91 (0.78–4.65); 0.150
Hyperlipidaemia 0.51 (0.17–1.53); 0.234 –
Smoking history 0.78 (0.37–1.66); 0.523 –
Renal impairment 1.16 (0.56–2.42); 0.688 –
Previous myocardial infarction 0.99 (0.34–2.87); 0.993 –
Previous percutaneous coronary intervention 1.41 (0.67–2.95); 0.365 –
Previous coronary artery bypass grafting 1.13 (0.43–2.98); 0.798 –
Previous peripheral revascularisation 0.83 (0.34–2.06); 0.705 –
Previous ischaemic stroke/transient ischaemic attack (0.30–3.32); 0.994 –
Coronary artery disease 0.97 (0.45–2,11); 0.951 –
Supra-aortic artery disease 0.75 (0.36–1.56); 0.441 –
Procedure related factors:
Bilateral PTA or PTA of one functioning kidney 2.57 (1.23–5.38); 0.011 18.6 (0.89–38.3); 0.058
PTA of right vs. left renal artery 0.99 (0.52–1.92); 0.989 –
Stenosis severity before primary PTA 1.01 (0.98–1.04); 0.322 –
Stenosis severity after primary PTA 1.03 (0.99–1.04); 0.332 –
Balloon angioplasty alone n/a n/a
Drug eluting stent implantation 0.79 (0.27–2.26); 0.662 –
Stent length 0.96 (0.87–1.05); 0.411 –
Stent diameter ≤ 5 mm 2.79 (1.29–6.02); 0.009 2.76 (1.09–6.97); 0.031
Predilatation 1.48 (1.25–4.93); 0.009 1.48 (0.67–3.26); 0.324
Maximal inflation pressure 1.13 (1.01–1.27); 0.028 1.15 (0.89–1.48); 0.268
Clinical outcome:
SBP at final follow-up visit 1.03 (1.01–1.04); 0.001 0.98 (0.93–1.03); 0.426
DBP at final follow-up visit 1.03 (1.00–1.06); 0.020 1.11 (0.09–1.24); 0.052
Creatinine level at final follow-up visit 1.00 (1.00–1.01); 0.033 1.00 (0.10–1.01); 0.772
eGFR at final follow-up visit 0.98 (0.97–1.00); 0.171 –
Change in BP and renal parameters at follow-up vs. 
baseline:
No SBP/DBP decrease of less than ≤ –1/–2 mm Hg 4.19 (1.91–9.23); < 0.001 4.15 (1.67–10.3); 0.002
Creatinine level increase ≥ 22 μmol/l 1.94 (0.88–4.26); 0.095 0.20 (0.02–2.18); 0.189
eGFR increase of ≤ 0.17 ml/min/1.73 m2 2.67 (1.19–5.98); 0.016 2.93 (1.08–7.91); 0.033
n/a – not applicable.
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and renal function is unpredictable and diversified; sec-
ondly, there are no pathognomonic symptoms indicative 
of RS; and finally, the effect of RS on clinical parameters 
is poorly investigated. The novelty of our present study 
was the identification of potential links between the 
change in BP and renal parameters and the incidence 
of RS. Our major finding is that the lack of significant 
decrease in either SBP (less than –1 mm Hg drop) and 
DBP (less than –2 mm Hg drop) at 6-12 months follow-
ing successful procedure was independently related to 
a  4.15-fold RS risk increase, while lack of renal func-
tion improvement (eGFR increase of less than 0.17 ml/
min/1.73 m2) was associated with 2.93-fold risk of ste-
nosis recurrence in multivariate Cox proportional hazard 
analysis. 
In line, Zeller et al., in a group of 447 patients who 
underwent 619 renal artery interventions, found an RS 
rate of 19% at 5 years [32]. Of these RS, 81% were asso-
ciated with recurrent symptoms: recurrent hypertension 
in 84%, or continuing deterioration in renal function in 
16%. Also, Lederman et al. observed that RS tended to be 
more common among patients who had renal functional 
deterioration or lack of BP decrease after the PTA [13].
The index vessel diameter – another predictor of RS 
identified in our present study – was also reported by 
other authors [13, 14, 33, 34]. While stent diameter cut-
off values related to RS risk differ between the studies, 
the general rule was that smaller vessels have a  high-
er RS rate, e.g. in the Lederman study, the RS rate was 
36.0% for vessels with a reference diameter < 4.5 mm, 
compared with 15.8% in vessels with reference diameter 
4.5 to 6.0 mm, and 6.5% in vessels with reference diam-
eter exceeding 6.0 mm (p < 0.001) [13].
Consistently, Vignali et al. and Djavidani et al. report-
ed a lower rate of RS in patients with stent diameter of 
6 mm or more, compared with smaller diameters [14, 
34]. Vessel size is also reflected by lower patency rates. 
In small-diameter renal arteries (< 3.5 mm) treated with 
DES in patients with atherosclerotic renal artery stenosis, 
the 1-, 2-, and 5-year patency rates were 71%, 63%, and 
38%, respectively [35].
The RAS disease has heterogeneous aetiology, hence 
both the clinical and survival outcomes differ with re-
spect to whether arteritis, FMD, or atherosclerosis is its 
background [36, 37]. 
Iwashima et al. paid attention to differences between 
RS risk factors depending on the RAS aetiology. In athero-
sclerotic lesions, independent predictors of RS were ini-
tial degree of RAS > 90% (HR = 3.95; 95% CI: 1.14–24.95) 
as well as the presence of cardiovascular disease (2.84; 
95% CI: 1.16–8.51) [11]. While FMD was associated with 
RS risk itself (HR = 2.65; 95% CI: 1.10–5.95), of note the 
stenting rate in FMD patients was 34% in this study [11]. 
In our present study, the seven-year Kaplan-Meier RS-
free survival curves differed significantly depending on 
the RAS aetiology. The rates of vessel patency at 1, 2, 3, 
and 7 years after PTA were 100% in FMD, while 95.6, 92, 
88, and 83.9% in atherosclerosis, as well as 71.4, 39.7, 
39.7, and 39.7% in vasculitis (p < 0.001).
It is well known that balloon angioplasty without 
stenting is sufficient in the majority FMD cases with high 
patency rates and cure of hypertension in the majority of 
patients [37]. In general, acute effect and long-term dura-
bility after PTA for FMD-related lesions are good in most 
treated patients, especially in the case of lesions charac-
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Figure 2. Kaplan Meier curves: A – restenosis-free survival based on the RAS aetiology, B – primary and second-
ary renal artery patency in the whole study group
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main artery. In such cases redo procedures are needed in 
6–34% of treated patients [11, 37, 38].
In our study group all FMD-related lesions were eli-
gible for revascularisation limited to balloon angioplasty 
alone without the need of stent implantation. However, 
it should be emphasised that our good results regarding 
acute and long-term patency of treated FMD-related le-
sions may as well reflect serendipity conditioned by no 
need of stenting and the small group of treated lesions. 
Indeed, these results should not be generalised and tak-
en for granted because a 100% RS-free rate after FMD 
revascularisation has not been reported. 
The study by Park et al. concerning long-term outcome 
of endovascular treatment of RAS related to Takayasu 
arteritis demonstrated better long-term patency and 
similar clinical benefit on renovascular hypertension for 
balloon angioplasty compared with stent placement and 
concluded that in this kind of RAS aetiology stent place-
ment should be reserved for obvious angioplasty failure 
[36]. Furthermore, our study, with stenting in the major-
ity of cases, indicated fast loss (60% in 2 years) of the 
vessel patency in vasculitis when a stent was implanted. 
In atherosclerotic RAS the other potential risk factor of 
RS, supported by some researchers, but not in our study, 
is the stent type. Published data concerning the impact of 
BMS and DES on restenosis prevention resulted in con-
flicting conclusions, favouring DES implantation in two out 
of three publish studies. Hence, in patients with small re-
nal arteries the use of DES seems reasonable [12, 39, 40].
In the study by Corriere et al. decreased risk of RS 
was associated with preoperative statin use (HR = 0.35; 
95% CI: 0.16–0.74; p = 0.006) and increased preoperative 
DBP (HR = 0.70 per 10 mm Hg increase in preoperative 
DBP; 95% CI: 0.49–0.99; p = 0.049) [15]. However, statins 
were not confirmed in the study by Jundt et al., who re-
ported history of stroke to be an independent risk factor 
of RS in patients with RAS and renal impairment at base-
line [35]. 
In our study, patients with RS treated with repeated 
angioplasty showed recurrence in 20% of cases. This is in 
line with results of Stone et al. and Zeller et al. [16, 32].
 Our patients were innumerous and were managed 
by different techniques, thus complex analysis is not 
possible. The data from Zeller et al. indicated that re-oc-
currence of RS was more likely in smaller vessel diame-
ters with an incidence of 57% in 3-4 mm; 42% in 5 mm; 
20% in 6 mm, and 14% in 7 mm vessel diameters [32]. 
Nevertheless, repeated endovascular treatment of RS is 
possible and effective.
Conclusions
The average RS rate was 14%, accounting for 60% 
in inflammatory, 17% in atherosclerotic, and 0% in FMD 
RAS at 24 months following PTA. Lack of the SBP/DBP 
and eGFR improvement following PTA, as well as inflam-
matory aetiology and lower stent diameter are inde-
pendently associated with increased risk of RS. Repeated 
PTA is effective, but recurrent RS occurs in 20% of cases. 
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